TG Therapeutics Cash Flow Statement
NASDAQ: TGTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
TG Therapeutics free cash flow
In fiscal 2025, TG Therapeutics generated -$24.8 million of operating cash flow and spent $214,000 on capital expenditures. That left free cash flow of -$25.0 million, a free-cash-flow margin of -4.1% of revenue. TG Therapeutics returned $91.2 million to shareholders through share repurchases.
Summary generated from market data by MetaCap's automated system. Methodology
TG Therapeutics cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 447.18M | 23.38M | 12.67M | -198.34M | -348.10M | -279.38M | -172.87M | -173.48M | -118.48M | -78.25M |
| Net Income growth (YoY) | +1812.41% | +84.52% | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 59.00K | 68.00K | 211.00K | 303.00K | 282.00K | 158.00K | 100.00K | 88.00K | 82.00K | 63.00K |
| Stock-Based Compensation | 64.67M | 42.54M | 37.93M | 44.66M | 61.27M | 80.29M | 11.34M | 12.89M | 15.90M | 7.50M |
| Change in Working Capital | -147.63M | -104.62M | -82.13M | -9.77M | 14.45M | -152.00K | -152.00K | -152.00K | -152.00K | -152.00K |
| Operating Cash Flow | -24.77M | -40.52M | -31.41M | -176.17M | -295.63M | -214.51M | -132.81M | -128.93M | -93.76M | -61.59M |
| Capital Expenditures | -214.00K | -45.00K | 0 | -14.00K | -401.00K | -357.00K | -131.00K | -90.00K | -2.00K | -344.00K |
| Investing Cash Flow | 13.80M | -1.04M | -50.65M | -20.01M | -332.00K | -24.51M | -718.00K | 1.18M | -8.21M | 26.55M |
| Share Repurchases | -91.24M | -8.76M | 0 | 0 | — | — | — | — | — | — |
| Debt Issued | 0 | 244.81M | 25.00M | 0 | 70.00M | — | — | — | — | — |
| Financing Cash Flow | -89.73M | 128.53M | 72.70M | -391.00K | 41.42M | 679.83M | 204.21M | 113.64M | 133.66M | 5.02M |
| Net Change in Cash | -100.70M | 86.97M | -9.36M | -196.57M | -254.55M | 440.81M | 70.69M | -14.11M | 31.69M | -30.03M |
| Free Cash Flow | -24.99M | -40.56M | -31.41M | -176.18M | -296.04M | -214.86M | -132.94M | -129.01M | -93.76M | -61.93M |
This table shows 10 annual periods of TG Therapeutics's cash flow statement, from FY 2025 back to FY 2016, across 13 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow TGTX's reporting calendar. What is a cash flow statement?